Table 2.

Number of patients experiencing side effects during TNFi treatment

	Adalimumab	Infliximab	Total
Infusion-related reaction
Mild	0 (0)	6 (18)	6 (14)
Severe	0 (0)	3 (9)	3 (7)
Anaphylaxis
Anaphylaxis	0 (0)	1 (3)	1 (2)
Infection
Respiratory	1 (11)	3 (9)	4 (9)
Abscesses	0 (0)	1 (3)	1 (2)
Miliary tuberculosis	0 (0)	1 (3)	1 (2)
Cellulitis with septicaemia	0 (0)	1 (3)	1 (2)
Neoplasia
Non-Hodgkin’s lymphoma	1 (11)	0 (0)	1 (2)
Cutaneous
Injection site cutaneous	1 (11)	0 (0)	1 (2)
Psoriasis	0 (0)	1 (3)	1 (2)
Alopecia	1 (11)	0 (0)	1 (2)
Other rash	0 (0)	4 (12)	4 (9)
Other
Lupus	0 (0)	2 (6)	2 (5)
Myalgia	2 (22)	0 (0)	2 (5)
Fatigue	1 (11)	3 (9)	4 (9)
Headache	2 (22)	0 (0)	2 (5)
Arthralgia	2 (22)	1 (3)	3 (7)
Back pain	0 (0)	1 (3)	1 (2)
Nausea	2 (22)	0 (0)	2 (5)
Haematuria	1 (11)	0 (0)	1 (2)
Night sweats	1 (11)	0 (0)	1 (2)
Gout	1 (11)	0 (0)	1 (2)
Mood disturbance	1 (11)	0 (0)	1 (2)
Total	17	28	45

Percentage proportions are shown in brackets.

TNFi, tumour necrosis factor-alpha inhibitor.